Agenus (AGEN) Reports 100% Major Pathologic Response in dMMR Combination Cohort

What happened

Agenus reported that all 14 patients in its dMMR/MSI-H BOT+BAL combination cohort achieved a major pathologic response, and 13 achieved a complete response. As of February 9, 2026, no patients in that cohort had recurrence; 12-month event-free survival was 100% in both combination cohorts.

Confirmed

Global impact / market context

The response results could support further testing of Agenus’s combination treatment and, if later studies confirm lasting benefit, potentially strengthen its case for development. That could help the company attract investment or funding, while successful treatment could eventually generate revenue; however, the small, non-randomized study does not establish benefit versus alternatives.

Analyst inference

The article describes early Phase 2 results from 56 patients, with everyone undergoing surgery. It also reports 100% 12-month event-free survival in both cohorts, but follow-up was limited, and the study had no randomized comparison to show whether the treatment caused the outcomes.

Confirmed

What to watch

1. Watch for larger controlled studies that compare the combination with alternatives; those results could clarify whether the high response rates translate into better patient outcomes and support further development. Analyst inference
2. Track longer follow-up for recurrence and event-free survival, meaning time without recurrence or other specified events, because current observation periods were limited and lasting benefit remains uncertain. Analyst inference
3. The article reports all 56 patients underwent surgery and planned timing was preserved in 98%; further results could clarify whether this approach remains feasible in larger studies. Confirmed

Evidence

• Original source link unavailable